SRC
ABBV icon

Sage Rhino Capital’s AbbVie ABBV Stock Holding History

Sage Rhino Capital’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$504K Sell
2,317
-6
-0.3% -$1.33K 0.09% 145
2025
Q4 		$531K Sell
2,323
-107
-4% -$24.4K 0.1% 142
2025
Q3 		$563K Buy
2,430
+125
+5% +$25.5K 0.11% 139
2025
Q2 		$428K Buy
2,305
+5
+0.2% +$929 0.09% 143
2025
Q1 		$482K Sell
2,300
-17
-0.7% -$3.31K 0.11% 137
2024
Q4 		$412K Sell
2,317
-63
-3% -$11.6K 0.09% 148
2024
Q3 		$470K Sell
2,380
-71
-3% -$13.3K 0.1% 143
2024
Q2 		$420K Buy
2,451
+102
+4% +$16.9K 0.1% 140
2024
Q1 		$428K Buy
2,349
+85
+4% +$14.6K 0.1% 142
2023
Q4 		$351K Sell
2,264
-41
-2% -$5.98K 0.09% 144
2023
Q3 		$344K Buy
2,305
+28
+1% +$4.11K 0.1% 146
2023
Q2 		$307K Sell
2,277
-406
-15% -$59.5K 0.09% 157
2023
Q1 		$428K Buy
2,683
+368
+16% +$56.3K 0.12% 128
2022
Q4 		$374K Sell
2,315
-2
-0.1% -$307 0.12% 134
2022
Q3 		$311K Sell
2,317
-171
-7% -$24.5K 0.12% 124
2022
Q2 		$381K Sell
2,488
-308
-11% -$47.1K 0.15% 117
2022
Q1 		$453K Sell
2,796
-35
-1% -$5.08K 0.14% 127
2021
Q4 		$383K Buy
2,831
+75
+3% +$8.86K 0.11% 138
2021
Q3 		$297K Buy
2,756
+71
+3% +$8.11K 0.09% 151
2021
Q2 		$302K Buy
2,685
+59
+2% +$6.64K 0.09% 152
2021
Q1 		$284K Buy
2,626
+40
+2% +$4.28K 0.09% 139
2020
Q4 		$277K Buy
2,586
+29
+1% +$2.79K 0.11% 137
2020
Q3 		$224K Sell
2,557
-5
-0.2% -$471 0.11% 137
2020
Q2 		$252K Buy
+2,562
New +$226K 0.13% 124

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sage Rhino Capital's ABBV Position: Q1 2026 in Review

Sage Rhino Capital reduced its AbbVie (ABBV) stake by 0.26% in Q1 2026, selling an estimated $1.33K and leaving 2,317 shares worth $504K. The position accounts for 0.09% of the portfolio, ranked #145.

Sage Rhino Capital first reported a position in ABBV in Q2 2020 and has held it in 24 quarters since. The position peaked at $563K in Q3 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Sage Rhino Capital held 2,317 shares of AbbVie worth $504K as of Q1 2026.
  • Sage Rhino Capital sold 6 AbbVie shares in Q1 2026, an estimated $1.33K.
  • AbbVie made up 0.09% of Sage Rhino Capital's portfolio in Q1 2026, its #145 holding.
  • Sage Rhino Capital first reported a position in AbbVie in Q2 2020 and has held it in 24 quarters since.
  • Sage Rhino Capital's AbbVie position peaked at $563K in Q3 2025.
  • 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Sage Rhino Capital's 13F filing for Q1 2026, filed 28 Apr 2026.